Treatment of Depression With Quetiapine

Inclusion Criteria: Male and female subjects between the ages of 18 to 75 years. A Structured Clinical Interview for the DSM-IV (SCID) derived diagnosis of major depression with psychosis, single or recurrent episode (unipolar or bipolar). Subjects may have an anxiety disorder or an additional mood disorder such as dysthymia. Baseline 24-item Hamilton Depression Rating Scale (HDRS) score of greater than or equal to 21. A baseline Positive and Negative Syndrome Scale (PANSS) score of greater than or equal to 4 on at least one of the 4 psychosis items. Women of childbearing potential must agree to practice a medically accepted means of contraception. Length of current episode no longer than 3 months. Exclusion Criteria: Pregnant or lactating women Women of child-bearing age who refuse a pregnancy test or who refuse to use a contraceptive technique when sexually active. Persons with other psychotic disorders; a mood disorder due to a general medical condition or substance-induced; substance dependence disorder in the last 6 months; substance abuse in the last 6 months or a dementing disorder are excluded. Persons with serious, unstable medical illnesses. Subjects who have been intolerant or nonresponsive to adequate trials of quetiapine, haloperidol and/or citalopram. Subjects who have received an injectable decanoate medication within 1 half life of the medication (i.e, 4 weeks for haloperidol or 2 weeks for fluphenazine). Subjects who have received fluoxetine within 4 weeks prior to randomization. Subjects who have received aripiprazole within 2 weeks prior to randomization. Subjects who have been treated with ECT within the last 6 months.